In recent years, photodynamic therapy (PDT) has shown much promise for the local and selective destruction of malignant tumours. Although tumour destruction is believed to be mediated through the production of highly reactive intermediate singlet oxygen by photoactivated hematoporphyrins (Weishaupt et al., 1986) , considerable evidence has accumulated to suggest that the primary site of photodynamic damage is the small vessels and capillaries of the tumours (Nelson et al., 1988; Berenbaum et al., 1986) . Some studies have shown vascular effects occurring with PDT such as the fall of tumour -blood flow (Selman et al., 1984; Wieman et al., 1988) and the shutdown of tumour vessels (Henderson et al., 1985) . In one report a complete cessation of tumour blood flow was described in rat tumours after PDT (Star et al., 1986) . In solid tumours the drug uptake is limited by the tissue perfusion rate, the membrane permeability and the transport across the vessel wall (Gerlowski et al., 1986) . Therefore, it seemed plausible that vasoactive drugs might influence tumour destruction by PDT. In particular the calcium channel blockers have generated much interest in cancer research since it has been demonstrated that verapamil, the prototype calcium channel blocker, increases the cytostatic effects of adriamycin and vincristine (Tsuruo et al., 1983) and has a reversible antiproliferative effect itself (Schmidt et al., 1988) . Although the precise mechanism of action is not known, some studies indicate that verapamil inhibits the P-glycoprotein pump which drug-resistant tumour cells use to pump out anticancer agents (Ince et al., 1986; Garman et al., 1983) .
Recently an enhanced photodynamic destruction of tumours was described when verapamil was concurrently administered with the photosensitiser, or similarly when verapamil was injected after PDT, a delay of the regrowth of tumours was implicated (Cowled & Forbes, 1989 ). In contrast to these authors, who administered high doses of hematoporphyrin derivative (HPD, 30-50 mg kg-' body weight), we injected doses of hematoporphyrin derivative enriched with dihematoporphyrin-ether (DHE, 1.5 or 9mgkg-' body weight) according to previous experiments (Sroka et al., 1989a) . In our experiments we used two different tumour models to examine the effects of verapamil on the photodynamic destruction of tumours.
Our first tumour model, the isogeneic fibrosarcoma SSK-2 was implanted into the flank of female inbred C3H-mice. This fibrosarcoma grows with a doubling time of approximately 1.5 days. The tumour size was measured with calibration masks, gauged to the weight of tumours (Kummermehr & Trott, 1982) . The photodynamic efficiency was quantified by means of the tumour regrowth delay time, i.e. the time a tumour needs to regain a defined weight (Begg, 1980) . When the tumours reached a weight of 60 mg, the photosensitiser and verapamil, both diluted with saline solution, were injected intraperitoneally at a dose of 9 mg kg-' body weight according to previous experiments (Stocker, 1986 Photosan 3 (Seehof Laboratory, FRG), a hematoporphyrin derivative enriched with dihematoporphyrinether (DHE), was administered intraperitoneally to the animals at a concentration of 1.5 mg kg-' (human adenocarcinoma and fibrosarcoma SSK-2) and 9 mg kg-' (fibrosarcoma SSK-2) body weight.
Verapamil (Isoptin, Knoll AG, FRG), formulated for clinical use, was injected concurrently with the photosensitiser at a dose of 2 mg kg-' body weight. Twenty-four hours after application of of the drugs, the tumours were irradiated with laser light.
Tumours were treated with laser light tuned to the wavelength of 630 nm. The radiation was delivered from anto multiple inner reflection (Sroka et al., 1989b Our second in vivo model involves tumours of human adenocarcinoma of the colon which were transplanted into nude mice. In this model we examined the effects of verapamil and PDT on tumour destruction alone (Table III) . Under the conditions tested, verapamil did not enhance the photodynamic destruction of the human colon carcinoma. Verapamil plus PDT had no effect on the degree of tumour tissue necrosis when compared to PDT alone. The extent of tumour necrosis was not influenced by verapamil alone (group C), DHE alone (group B) or light without drugs (group D) compared to controls (group A).
The process in which tumour damage is caused by photodynamic therapy is complex dependent on many different factors. Experimental studies have shown that the most important parameters are the applied energy density, the concentration of the administered photosensitiser in the tissue and the time interval between irradiation and administration of the photosensitiser (Barr et al., 1989; Potter et al., 1987 (Wooton et al., 1988) .
In view of the results found in our two different tumour models, we conclude that verapamil does not increase photodynamic damage concurrently administered with low doses of DHE in our in vivo models. It could be demonstrated that for a low photosensitiser concentration neither a regrowth delay nor an increased extent of tumour tissue necrosis is achieved. However, in other studies intracellular concentrations of cytotoxic agents such as adriamycin and vincristine were increased, suggesting that verapamil improved uptake and inhibited transport of drugs through the cell membrane (Tsuruo et -al., 1983) . Thus the supposed pharmacological mechanism is the existence of a drug elimination pathway in the plasma membrane of cancer cells. A possible explanation could be the concept that verapamil blocks the P-glycoprotein pump which tumour cells use to transport anticancer drugs out of the cell (Ince et al., 1986) . But a certain intracellular concentration of the applied drug has to be reached to activate the P-glycoprotein mechanism.
It is known that the photosensitiser concentration ratio between tumour and normal tissue is only 2.5:1 (Barr et al., 1989) . In accordance with the P-glycoprotein mechanism hypothesis, this photosensitiser concentration could be too low to trigger this drug elimination pathway and might be the reason why we did not find an enhanced destruction of Differences between A through D and E, F are significant (P <0.05). aWith a photosensitiser concentration of 1.5 mg kg-' body weight. Cowled and Forbes used a different tumour model with different drug concentrations. Therefore, the question remains to be solved whether the lower photosensitiser concentration or the type of tumour tested is the reason why we did not find an enhanced tumour destruction in combination with verapamil. From our results it seems to be clear that there is no generality in the phenomenon described by Cowled and Forbes. In spite of our negative experiments, the possible enhancement of photodynamic destruction of tumours by vasoactive drugs deserve further investigations. In a recent study, norverapamil, a mayor metabolite of verapamil with no systemic side effects, has proved to be as effective as verapamil (Merry et al., 1989) offering new possibilities in testing vasoactive drugs and photodynamic therapy.
For low dose administration of DHE, our current experimental strategies comprise different potential modifiers such as the application of glucose (Thomas & Girotti, 1989) or improved targeting with liposomes (Jori et al., 1986) or monoclonal antibodies (Mew et al., 1983) .
